What is Leerink Partnrs’ Forecast for LRMR FY2024 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at Leerink Partnrs raised their FY2024 EPS estimates for shares of Larimar Therapeutics in a report released on Wednesday, October 30th. Leerink Partnrs analyst J. Park now anticipates that the company will earn ($1.17) per share for the year, up from their prior forecast of ($1.51). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($1.85) EPS, FY2026 earnings at ($2.84) EPS and FY2027 earnings at ($2.41) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.13. During the same period in the previous year, the business posted ($0.21) EPS.

A number of other equities analysts have also weighed in on the stock. Wedbush started coverage on shares of Larimar Therapeutics in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 price objective on the stock. Baird R W raised shares of Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, September 4th. Robert W. Baird initiated coverage on shares of Larimar Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Larimar Therapeutics in a report on Thursday. Finally, Oppenheimer started coverage on Larimar Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $26.00 target price on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Larimar Therapeutics currently has an average rating of “Buy” and an average target price of $20.43.

Larimar Therapeutics Trading Down 6.0 %

Shares of LRMR stock opened at $7.74 on Monday. Larimar Therapeutics has a twelve month low of $2.18 and a twelve month high of $13.68. The business’s 50 day moving average is $7.34 and its two-hundred day moving average is $7.82. The company has a market capitalization of $493.87 million, a P/E ratio of -6.73 and a beta of 0.95.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new stake in shares of Larimar Therapeutics during the 1st quarter worth approximately $45,884,000. Janus Henderson Group PLC raised its holdings in Larimar Therapeutics by 52.2% during the first quarter. Janus Henderson Group PLC now owns 4,020,965 shares of the company’s stock worth $30,459,000 after purchasing an additional 1,379,900 shares during the last quarter. Vanguard Group Inc. raised its holdings in Larimar Therapeutics by 62.7% during the first quarter. Vanguard Group Inc. now owns 2,367,701 shares of the company’s stock worth $17,971,000 after purchasing an additional 912,458 shares during the last quarter. Driehaus Capital Management LLC boosted its position in Larimar Therapeutics by 20.8% during the second quarter. Driehaus Capital Management LLC now owns 1,314,106 shares of the company’s stock worth $9,527,000 after purchasing an additional 225,879 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Larimar Therapeutics by 30.2% in the second quarter. Millennium Management LLC now owns 1,018,135 shares of the company’s stock valued at $7,381,000 after purchasing an additional 235,865 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.